Start / PharmaTalkRadio / Updates on bintrafusp alfa m7824 clinical data

PharmaTalkRadio

Updates on Bintrafusp alfa/M7824 Clinical Data

23 min • 7 mars 2020

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Laureen Ojalvo, EMD Serono provides an overview of the moleculte Bintrafusp alfa/M7824. This molecule is an innovative, first-in-class bifunctional fusion protein composed of an anti-PD-L1 mAb fused with 2 extracellular domains of TGF-βRII (a TGF-β “trap”). The mechanism of action, pre-clinical and phase 1 studies of this molecule is discussed as well as an overview of the next wave of clinical development. To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Senaste avsnitt

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

12 augusti | 28 min

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

12 augusti | 28 min

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

25 juli | 29 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00